Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.3100
- TODAY'S CHANGE (%)-0.0900 (-2.6471%)
- Bid / Lots3.2900/ 6
- Ask / Lots3.4200/ 2
- Open / Previous Close3.4100 / 3.4000
- Day Range
- 52 Week Range
- Volume2,213,753
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 7453 | 3.41 |
| 09:34 ET | 3595 | 3.43 |
| 09:36 ET | 1200 | 3.45 |
| 09:38 ET | 800 | 3.445 |
| 09:41 ET | 200 | 3.43 |
| 09:45 ET | 800 | 3.41 |
| 09:48 ET | 3948 | 3.38 |
| 09:50 ET | 1284 | 3.39 |
| 09:52 ET | 9944 | 3.39 |
| 09:54 ET | 1408 | 3.39 |
| 09:59 ET | 1000 | 3.3892 |
| 10:01 ET | 7600 | 3.36 |
| 10:03 ET | 10799 | 3.38 |
| 10:12 ET | 300 | 3.38 |
| 10:14 ET | 100 | 3.38 |
| 10:19 ET | 200 | 3.39 |
| 10:21 ET | 500 | 3.39 |
| 10:24 ET | 500 | 3.38 |
| 10:26 ET | 850 | 3.39 |
| 10:28 ET | 1725 | 3.38 |
| 10:30 ET | 305 | 3.37 |
| 10:32 ET | 517 | 3.369 |
| 10:35 ET | 2436 | 3.335 |
| 10:37 ET | 415 | 3.33 |
| 10:44 ET | 669 | 3.34 |
| 10:50 ET | 100 | 3.34 |
| 10:51 ET | 4200 | 3.34 |
| 10:53 ET | 548 | 3.34 |
| 11:00 ET | 2829 | 3.32 |
| 11:02 ET | 600 | 3.315 |
| 11:06 ET | 150 | 3.31 |
| 11:08 ET | 100 | 3.32 |
| 11:09 ET | 100 | 3.32 |
| 11:11 ET | 500 | 3.31 |
| 11:13 ET | 2538 | 3.3 |
| 11:15 ET | 1550 | 3.305 |
| 11:18 ET | 500 | 3.29 |
| 11:20 ET | 100 | 3.3 |
| 11:22 ET | 500 | 3.295 |
| 11:24 ET | 1700 | 3.305 |
| 11:26 ET | 702 | 3.3 |
| 11:36 ET | 3614 | 3.31 |
| 11:38 ET | 14291 | 3.3 |
| 11:40 ET | 5713 | 3.31 |
| 11:42 ET | 10095 | 3.32 |
| 11:44 ET | 400 | 3.3 |
| 11:45 ET | 1274 | 3.29 |
| 11:49 ET | 922 | 3.29 |
| 11:51 ET | 2079 | 3.32 |
| 11:56 ET | 1097 | 3.32 |
| 12:00 ET | 200 | 3.33 |
| 12:02 ET | 10790 | 3.34 |
| 12:05 ET | 1009 | 3.35 |
| 12:07 ET | 930 | 3.339 |
| 12:09 ET | 307 | 3.335 |
| 12:12 ET | 300 | 3.33 |
| 12:14 ET | 138 | 3.335 |
| 12:16 ET | 3226 | 3.35 |
| 12:18 ET | 440 | 3.3459 |
| 12:20 ET | 401 | 3.35 |
| 12:21 ET | 130 | 3.35 |
| 12:23 ET | 404 | 3.35 |
| 12:27 ET | 100 | 3.36 |
| 12:30 ET | 302 | 3.35 |
| 12:32 ET | 6001 | 3.37 |
| 12:34 ET | 295 | 3.37 |
| 12:36 ET | 1140 | 3.37 |
| 12:38 ET | 257 | 3.3799 |
| 12:41 ET | 446 | 3.36 |
| 12:43 ET | 106 | 3.36 |
| 12:48 ET | 1741 | 3.36 |
| 12:50 ET | 629 | 3.35 |
| 12:52 ET | 506 | 3.36 |
| 12:54 ET | 293 | 3.36 |
| 01:01 ET | 200 | 3.35 |
| 01:03 ET | 334 | 3.36 |
| 01:08 ET | 440 | 3.36 |
| 01:10 ET | 100 | 3.36 |
| 01:14 ET | 200 | 3.36 |
| 01:15 ET | 453 | 3.37 |
| 01:17 ET | 200 | 3.38 |
| 01:19 ET | 100 | 3.375 |
| 01:21 ET | 1292 | 3.38 |
| 01:24 ET | 570 | 3.37 |
| 01:26 ET | 386 | 3.36 |
| 01:28 ET | 200 | 3.37 |
| 01:30 ET | 2802 | 3.35 |
| 01:32 ET | 3189 | 3.34 |
| 01:33 ET | 500 | 3.34 |
| 01:35 ET | 800 | 3.32 |
| 01:37 ET | 500 | 3.32 |
| 01:39 ET | 785 | 3.32 |
| 01:42 ET | 200 | 3.32 |
| 01:44 ET | 541 | 3.325 |
| 01:46 ET | 849 | 3.33 |
| 01:48 ET | 4199 | 3.34 |
| 01:50 ET | 133 | 3.33 |
| 01:51 ET | 6170 | 3.32 |
| 01:53 ET | 138 | 3.33 |
| 01:55 ET | 1385 | 3.33 |
| 01:57 ET | 498 | 3.33 |
| 02:00 ET | 1100 | 3.325 |
| 02:02 ET | 650 | 3.33 |
| 02:04 ET | 100 | 3.33 |
| 02:06 ET | 599 | 3.33 |
| 02:09 ET | 537 | 3.32 |
| 02:11 ET | 4234 | 3.32 |
| 02:13 ET | 475 | 3.335 |
| 02:18 ET | 259 | 3.335 |
| 02:20 ET | 331 | 3.33 |
| 02:22 ET | 200 | 3.33 |
| 02:24 ET | 527 | 3.34 |
| 02:26 ET | 331 | 3.345 |
| 02:27 ET | 200 | 3.35 |
| 02:29 ET | 100 | 3.3485 |
| 02:31 ET | 435 | 3.34 |
| 02:33 ET | 3470 | 3.3363 |
| 02:36 ET | 200 | 3.33 |
| 02:38 ET | 100 | 3.33 |
| 02:40 ET | 500 | 3.33 |
| 02:42 ET | 988 | 3.34 |
| 02:44 ET | 100 | 3.345 |
| 02:45 ET | 334 | 3.345 |
| 02:47 ET | 700 | 3.3437 |
| 02:49 ET | 100 | 3.345 |
| 02:51 ET | 200 | 3.345 |
| 02:54 ET | 100 | 3.34 |
| 02:58 ET | 593 | 3.35 |
| 03:00 ET | 351 | 3.35 |
| 03:02 ET | 564 | 3.35 |
| 03:03 ET | 4846 | 3.32 |
| 03:05 ET | 397 | 3.32 |
| 03:07 ET | 1106 | 3.33 |
| 03:09 ET | 2434 | 3.325 |
| 03:12 ET | 100 | 3.32 |
| 03:14 ET | 205 | 3.325 |
| 03:16 ET | 700 | 3.325 |
| 03:20 ET | 200 | 3.325 |
| 03:21 ET | 330 | 3.325 |
| 03:23 ET | 400 | 3.32 |
| 03:32 ET | 2027 | 3.315 |
| 03:36 ET | 830 | 3.315 |
| 03:38 ET | 1306 | 3.32 |
| 03:39 ET | 300 | 3.315 |
| 03:41 ET | 500 | 3.315 |
| 03:43 ET | 1100 | 3.31 |
| 03:45 ET | 2153 | 3.305 |
| 03:48 ET | 891 | 3.305 |
| 03:50 ET | 1135 | 3.305 |
| 03:52 ET | 13841 | 3.31 |
| 03:54 ET | 5327 | 3.31 |
| 03:56 ET | 2058 | 3.31 |
| 03:57 ET | 1860 | 3.31 |
| 03:59 ET | 784685 | 3.31 |
Jun 25, 2024
Jun 20, 2024
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below, from 11:02AM ET on Thursday Jun 13, 2024 by Dow Jones
11:02AM ET on Thursday Jun 13, 2024 by Dow JonesAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 193.1M | -6.5x | --- |
Rani Therapeutics Holdings Inc | 196.1M | -2.9x | --- |
Pyxis Oncology Inc | 189.0M | -2.4x | --- |
Trevi Therapeutics Inc | 186.7M | -8.8x | --- |
Prelude Therapeutics Inc | 203.2M | -2.0x | --- |
Design Therapeutics Inc | 182.5M | -3.2x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $193.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.44 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
